Literature DB >> 20660705

TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis.

Stacey L Demento1, Nathalie Bonafé, Weiguo Cui, Susan M Kaech, Michael J Caplan, Erol Fikrig, Michel Ledizet, Tarek M Fahmy.   

Abstract

Vaccines that activate humoral and cell-mediated immune responses are urgently needed for many infectious agents, including the flaviviruses dengue and West Nile (WN) virus. Vaccine development would be greatly facilitated by a new approach, in which nanoscale modules (Ag, adjuvant, and carrier) are assembled into units that are optimized for stimulating immune responses to a specific pathogen. Toward that goal, we formulated biodegradable nanoparticles loaded with Ag and surface modified with the pathogen-associated molecular pattern CpG oligodeoxynucleotides. We chose to evaluate our construct using a recombinant envelope protein Ag from the WN virus and tested the efficiency of this system in eliciting humoral and cellular responses and providing protection against the live virus. Animals immunized with this system showed robust humoral responses polarized toward Th1 immune responses compared with predominately Th2-biased responses with the adjuvant aluminum hydroxide. Immunization with CpG oligodeoxynucleotide-modified nanoparticles resulted in a greater number of circulating effector T cells and greater activity of Ag-specific lymphocytes than unmodified nanoparticles or aluminum hydroxide. Ultimately, compared with alum, this system offered superior protection in a mouse model of WN virus encephalitis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660705      PMCID: PMC3753007          DOI: 10.4049/jimmunol.1000768

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  61 in total

1.  Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles.

Authors:  Hong Shen; Anne L Ackerman; Virginia Cody; Alessandra Giodini; Ella R Hinson; Peter Cresswell; Richard L Edelson; W Mark Saltzman; Douglas J Hanlon
Journal:  Immunology       Date:  2006-01       Impact factor: 7.397

2.  Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes.

Authors:  David H Holman; Danher Wang; Kanakatte Raviprakash; Nicholas U Raja; Min Luo; Jianghui Zhang; Kevin R Porter; John Y Dong
Journal:  Clin Vaccine Immunol       Date:  2006-12-27

3.  Preparation and immunogenic properties of a recombinant West Nile subunit vaccine.

Authors:  Michael M Lieberman; David E Clements; Steven Ogata; Gordon Wang; Gloria Corpuz; Teri Wong; Tim Martyak; Lynne Gilson; Beth-Ann Coller; Julia Leung; Douglas M Watts; Robert B Tesh; Marina Siirin; Amelia Travassos da Rosa; Tom Humphreys; Carolyn Weeks-Levy
Journal:  Vaccine       Date:  2006-08-30       Impact factor: 3.641

4.  Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus.

Authors:  L Hannah Gould; Jianhua Sui; Harald Foellmer; Theodore Oliphant; Tian Wang; Michel Ledizet; Akikazu Murakami; Kristin Noonan; Cassandra Lambeth; Kalipada Kar; John F Anderson; Aravinda M de Silva; Michael S Diamond; Raymond A Koski; Wayne A Marasco; Erol Fikrig
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

5.  CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system.

Authors:  Elizabeth M Sitati; Michael S Diamond
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

6.  Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes.

Authors:  W M Li; M B Bally; M P Schutze-Redelmeier
Journal:  Vaccine       Date:  2001-10-12       Impact factor: 3.641

7.  A recombinant envelope protein vaccine against West Nile virus.

Authors:  Michel Ledizet; Kalipada Kar; Harald G Foellmer; Tian Wang; Sandra L Bushmich; John F Anderson; Erol Fikrig; Raymond A Koski
Journal:  Vaccine       Date:  2005-04-06       Impact factor: 3.641

8.  Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection.

Authors:  Jang-Hann J Chu; Cern-Cher S Chiang; Mah-Lee Ng
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

9.  A live, attenuated recombinant West Nile virus vaccine.

Authors:  Thomas P Monath; Jian Liu; Niranjan Kanesa-Thasan; Gwendolyn A Myers; Richard Nichols; Alison Deary; Karen McCarthy; Casey Johnson; Thomas Ermak; Sunheang Shin; Juan Arroyo; Farshad Guirakhoo; Jeffrey S Kennedy; Francis A Ennis; Sharone Green; Philip Bedford
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-14       Impact factor: 11.205

10.  Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles.

Authors:  Xue-Qing Zhang; Christopher E Dahle; Nicki K Baman; Nathan Rich; George J Weiner; Aliasger K Salem
Journal:  J Immunother       Date:  2007 Jul-Aug       Impact factor: 4.456

View more
  51 in total

1.  Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction.

Authors:  James J Moon; Heikyung Suh; Adrienne V Li; Christian F Ockenhouse; Anjali Yadava; Darrell J Irvine
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-12       Impact factor: 11.205

Review 2.  Nanomedicine in GI.

Authors:  Hamed Laroui; David S Wilson; Guillaume Dalmasso; Khalid Salaita; Niren Murthy; Shanthi V Sitaraman; Didier Merlin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-12-09       Impact factor: 4.052

3.  Engineered Materials for Cancer Immunotherapy.

Authors:  Alexander S Cheung; David J Mooney
Journal:  Nano Today       Date:  2015-08-01       Impact factor: 20.722

Review 4.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

5.  Immunomodulatory nanoparticles ameliorate disease in the Leishmania (Viannia) panamensis mouse model.

Authors:  Alyssa L Siefert; Allison Ehrlich; María Jesús Corral; Karen Goldsmith-Pestana; Diane McMahon-Pratt; Tarek M Fahmy
Journal:  Biomaterials       Date:  2016-09-06       Impact factor: 12.479

Review 6.  Bio-inspired, bioengineered and biomimetic drug delivery carriers.

Authors:  Jin-Wook Yoo; Darrell J Irvine; Dennis E Discher; Samir Mitragotri
Journal:  Nat Rev Drug Discov       Date:  2011-07-01       Impact factor: 84.694

7.  Functionalized iron oxide nanoparticles for controlling the movement of immune cells.

Authors:  Ethan E White; Alex Pai; Yiming Weng; Anil K Suresh; Desiree Van Haute; Torkom Pailevanian; Darya Alizadeh; Ali Hajimiri; Behnam Badie; Jacob M Berlin
Journal:  Nanoscale       Date:  2015-05-07       Impact factor: 7.790

8.  Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus.

Authors:  Ming Yang; Matthew Dent; Huafang Lai; Haiyan Sun; Qiang Chen
Journal:  Vaccine       Date:  2017-06-29       Impact factor: 3.641

Review 9.  Applications and perspectives of nanomaterials in novel vaccine development.

Authors:  Yingbin Shen; Tianyao Hao; Shiyi Ou; Churan Hu; Long Chen
Journal:  Medchemcomm       Date:  2017-10-17       Impact factor: 3.597

Review 10.  West Nile Virus: biology, transmission, and human infection.

Authors:  Tonya M Colpitts; Michael J Conway; Ruth R Montgomery; Erol Fikrig
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.